S Dirajlal-Fargo1,2,3, L Shan3, A Sattar3, E Bowman4, J Gabriel4, M Kulkarni4, N Funderburg4, R Nazzinda5, V Musiime5, G A McComsey1,2,3. 1. University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 2. Rainbow Babies and Children's Hospital, Cleveland, OH, USA. 3. Case Western Reserve University, Cleveland, OH, USA. 4. Ohio State University School of Health and Rehabilitation Sciences, Columbus, OH, USA. 5. Joint Clinical Research Centre, Makerere University, Kampala, Uganda.
Abstract
OBJECTIVES: The risk of cardiometabolic complications in children with perinatally acquired HIV infection (PHIVs) and in perinatally HIV-exposed but uninfected children (HEUs) and its relationship to systemic inflammation and markers of gut integrity are not well established. In this current study, we assed insulin resitance in PHIV compared to HEUs and HIV unexposed uninfected children and explored potential association with intestinal damage biomarkers. METHODS: This was a cross-sectional study in PHIVs, HEUs and HIV-unexposed, uninfected children (HUUs) aged 2-10 years enrolled in Uganda. PHIVs were on stable antiretroviral therapy (ART) with HIV viral load < 400 HIV-1 RNA copies/mL. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). We measured markers of systemic inflammation, monocyte activation and gut integrity. Kruskal-Wallis tests were used to compare markers by HIV status; Pearson correlation and multiple linear regressions were used to assess associations of the HOMA-IR index with biomarkers of intestinal damage and translocation. RESULTS: Overall, 172 participants were enrolled in the study (57 PHIVs, 59 HEUs and 56 HUUs). The median age was 7.8 [interquartile range (IQR) 6.39, 8.84] years, 55% were female and the median body mass index (BMI) was 15 (IQR 14.3, 15.8) kg/m2 . Among PHIVs, the median CD4% was 37%, and 93% had viral load ≤ 20 copies/mL. PHIVs had higher waist:hip ratio, high-density lipoprotein (HDL) cholesterol, triglycerides and HOMA-IR index than the other groups (P ≤ 0.02). Factors correlated with insulin resistance included higher BMI and HDL cholesterol and lower soluble tumour necrosis factor receptor I (sTNFRI) (P ≤ 0.02). There was no correlation between any of the other inflammatory or gut biomarkers and HOMA-IR index (P ≥ 0.05). After adjusting for age and sTNFRI, BMI remained independently associated with the HOMA-IR index (β = 0.16; P < 0.01). CONCLUSIONS: Despite viral suppression, Ugandan PHIVs have disturbances in glucose metabolism. Higher BMI, and not immune activation or alteration of gut integrity, was associated with insulin resistance in this population.
OBJECTIVES: The risk of cardiometabolic complications in children with perinatally acquired HIV infection (PHIVs) and in perinatally HIV-exposed but uninfected children (HEUs) and its relationship to systemic inflammation and markers of gut integrity are not well established. In this current study, we assed insulin resitance in PHIV compared to HEUs and HIV unexposed uninfected children and explored potential association with intestinal damage biomarkers. METHODS: This was a cross-sectional study in PHIVs, HEUs and HIV-unexposed, uninfected children (HUUs) aged 2-10 years enrolled in Uganda. PHIVs were on stable antiretroviral therapy (ART) with HIV viral load < 400 HIV-1 RNA copies/mL. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). We measured markers of systemic inflammation, monocyte activation and gut integrity. Kruskal-Wallis tests were used to compare markers by HIV status; Pearson correlation and multiple linear regressions were used to assess associations of the HOMA-IR index with biomarkers of intestinal damage and translocation. RESULTS: Overall, 172 participants were enrolled in the study (57 PHIVs, 59 HEUs and 56 HUUs). The median age was 7.8 [interquartile range (IQR) 6.39, 8.84] years, 55% were female and the median body mass index (BMI) was 15 (IQR 14.3, 15.8) kg/m2 . Among PHIVs, the median CD4% was 37%, and 93% had viral load ≤ 20 copies/mL. PHIVs had higher waist:hip ratio, high-density lipoprotein (HDL) cholesterol, triglycerides and HOMA-IR index than the other groups (P ≤ 0.02). Factors correlated with insulin resistance included higher BMI and HDL cholesterol and lower soluble tumour necrosis factor receptor I (sTNFRI) (P ≤ 0.02). There was no correlation between any of the other inflammatory or gut biomarkers and HOMA-IR index (P ≥ 0.05). After adjusting for age and sTNFRI, BMI remained independently associated with the HOMA-IR index (β = 0.16; P < 0.01). CONCLUSIONS: Despite viral suppression, Ugandan PHIVs have disturbances in glucose metabolism. Higher BMI, and not immune activation or alteration of gut integrity, was associated with insulin resistance in this population.
Authors: Vanessa El Kamari; Carlee Moser; Corrilynn O Hileman; Judith S Currier; Todd T Brown; Liz Johnston; Peter W Hunt; Grace A McComsey Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Steve Innes; Kameelah L Abdullah; Richard Haubrich; Mark F Cotton; Sara H Browne Journal: Pediatr Infect Dis J Date: 2016-01 Impact factor: 2.129
Authors: Machline P Paganella; Rachel A Cohen; Donald R Harris; Ricardo de Souza Kuchenbecker; Rosa D Sperhacke; Sergio K Kato; Carmem L Oliveira da Silva; Fernanda T Sturzbecher; Ricardo H S Oliveira; Noris Pavía-Ruz; Rohan Hazra Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Daniel Blázquez; José Tomás Ramos-Amador; Talía Saínz; María José Mellado; Marta García-Ascaso; María Isabel De José; Pablo Rojo; María Luisa Navarro; María Ángeles Muñoz-Fernández; Jesús Saavedra; Miguel Angel Roa; Santiago Jiménez; José Beceiro; Luis Prieto; Milagros García Hortelano; María Isabel González-Tomé Journal: BMC Infect Dis Date: 2015-03-08 Impact factor: 3.090
Authors: Marcelo N Pedro; Guilherme Z Rocha; Dioze Guadagnini; Andrey Santos; Daniela O Magro; Heloisa B Assalin; Alexandre G Oliveira; Rogerio de Jesus Pedro; Mario J A Saad Journal: Front Endocrinol (Lausanne) Date: 2018-09-05 Impact factor: 5.555
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Adelzon A Paula; Mauro Schechter; Suely H Tuboi; José Claudio Faulhaber; Paula M Luz; Valdiléa G Veloso; Ronaldo I Moreira; Beatriz Grinsztejn; Lee H Harrison; Antonio G Pacheco Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240
Authors: Sophia Toe; Matthew Nagy; Zainab Albar; Jiao Yu; Abdus Sattar; Rashida Nazzinda; Victor Musiime; Samuel Etajak; Felix Walyawula; Grace A McComsey; Lynn M Atuyambe; Sahera Dirajlal-Fargo Journal: AIDS Date: 2022-02-07 Impact factor: 4.632